top of page
Connect_Logo_CMYK.jpg
Connect_Logo_CMYK.png
iStock-184117476.jpg

Publications & Presentations

Rademikibart - Respiratory
Rademikibart Treatment for Moderate-to-Severe, Uncontrolled Asthma: A Phase 2B Randomized Trial.

Kerwin E, Yang T, Su N, Guo J, Adivikolanu R, Longphre M, Wang J, Yun J, Pan W, Wei Z, Collazo R. Am J Respir Crit Care Med. 2025 Feb 25. doi: 10.1164/rccm.202409-1708OC. 

View
Rademikibart - Dermatology
Rademikibart monotherapy for moderate-to-severe atopic dermatitis in a 1-year, randomized, phase II trial (SEASIDE CHINA): initial two-week dosing, followed by two-week or four-week dosing

Zhang J, Silverberg JI, Guo J, et al.. Br J Dermatol. Published online September 2, 2025. doi:10.1093/bjd/ljaf347

View
Rademikibart (CBP-201), a next-generation monoclonal antibody targeting human IL-4Rα: Two phase I randomized trials, in healthy individuals and patients with atopic dermatitis.

Wang J, White J, Sansone KJ, Spelman L, Sinclair R, Yang X, Pan W, Wei Z. Clin Transl Sci. 2023 Dec;16(12):2614-2627. doi: 10.1111/cts.13656.

View
A Mini Review of the Impact of Baseline Disease Severity on Clinical Outcomes: Should We Compare Atopic Dermatitis Clinical Trials?

Silverberg JI, Ho S, Collazo R. Dermatol Ther (Heidelb). 2023 Dec;13(12):3019-3029. doi: 10.1007/s13555-023-01052-5.

View
Efficacy and safety of rademikibart (CBP-201), a next-generation mAb targeting IL-4Rα, in adults with moderate to severe atopic dermatitis: A phase 2 randomized trial (CBP-201-WW001).

Silverberg JI, Strober B, Feinstein B, Xu J, Guttman-Yassky E, Simpson EL, Li P, Longphre M, Song J, Guo J, Yun J, Williams B, Pan W, Ho S, Collazo R, Wei Z.  J Allergy Clin Immunol. 2024 Apr;153(4):1040-1049.e12. doi: 10.1016/j.jaci.2023.11.924.

View
Efficacy and safety of rademikibart (CBP-201), a next-generation mAb targeting IL-4Rα, in adults with moderate to severe atopic dermatitis: A phase 2 randomized trial (CBP-201-WW001).

Silverberg JI, Strober B, Feinstein B, Xu J, Guttman-Yassky E, Simpson EL, Li P, Longphre M, Song J, Guo J, Yun J, Williams B, Pan W, Ho S, Collazo R, Wei Z.  J Allergy Clin Immunol. 2024 Apr;153(4):1040-1049.e12. doi: 10.1016/j.jaci.2023.11.924.

View
Rademikibart - Discovery
Biologic Therapies Targeting Type 2 Signaling in Atopic Dermatitis: A Comparative Review of Structural and Thermodynamic Differences in Mechanism of Action

Bunick C. J Invest Dermatol. Published online August 6, 2025. doi:10.1016/j.jid.2025.06.1574.

View
Preclinical immunological characterization of rademikibart (CBP-201), a next-generation human monoclonal antibody targeting IL-4Rα, for the treatment of Th2 inflammatory diseases.

Zhang, L., Ding, Y., Wang, Q. et al. Sci Rep. 2023 Jul 31;13(1):12411. doi: 10.1038/s41598-023-39311-2.

View
bottom of page